We are live on ! Find out more
NXTC icon

NextCure
NXTC

30 hedge funds and large institutions have $5.65M invested in NextCure in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.44% less ownership

Funds ownership: 4.57% → 3.13% (-1.4%)

21% less funds holding

Funds holding: 38 → 30 (-8)

23% less capital invested

Capital invested by funds: $7.38M → $5.65M (-$1.73M)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

Holders
30
Holders Change
-8
Holders Change %
-21.05%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
6
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCC
Cable Car Capital
California
+$39.4K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$13.2K
3
Renaissance Technologies
Renaissance Technologies
New York
+$9.38K
4
VCIM
Velan Capital Investment Management
Georgia
+$8.95K
5
UBS Group
UBS Group
Switzerland
+$1.69K

Top Sellers

Rank Fund Capital Flow
1
P
Pfizer
New York
-$776K
2
O
OrbiMed
New York
-$548K
3
TCM
Tang Capital Management
California
-$194K
4
Citigroup
Citigroup
New York
-$176K
5
Federated Hermes
Federated Hermes
Pennsylvania
-$151K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$1.23M – – –
AAA
2
Affinity Asset Advisors
New York
$1.06M – – –
P
3
Pfizer
New York
$870K -$776K -144,510 -92%
Citigroup
4
Citigroup
New York
$472K -$176K -32,825 -28%
Vanguard Group
5
Vanguard Group
Pennsylvania
$401K -$51.6K -9,609 -12%
CCC
6
Cable Car Capital
California
$349K +$39.4K +7,336 +13%
Renaissance Technologies
7
Renaissance Technologies
New York
$230K +$9.38K +1,748 +4%
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$223K – – –
BlackRock
9
BlackRock
New York
$173K -$80.8K -15,056 -32%
CPA
10
Cardiff Park Advisors
California
$121K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$106K -$2.9K -540 -3%
Macquarie Group
12
Macquarie Group
Australia
$69K – – –
SCM
13
Sio Capital Management
New York
$60.4K +$585 +109 +1%
ACM
14
ADAR1 Capital Management
Texas
$54.3K -$896 -167 -2%
AC
15
Armistice Capital
New York
$47.8K – – –
Barclays
16
Barclays
United Kingdom
$31.1K – – –
State Street
17
State Street
Massachusetts
$30.1K – – –
Citadel Advisors
18
Citadel Advisors
Florida
$27.1K -$14.2K -2,650 -35%
Northern Trust
19
Northern Trust
Illinois
$21.8K – – –
VCIM
20
Velan Capital Investment Management
Georgia
$20.7K +$8.95K +1,667 +80%
IC
21
IEQ Capital
California
$17.2K – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$13.6K +$13.2K +2,459 New
HSBC Holdings
23
HSBC Holdings
United Kingdom
$8.09K – – –
SSA
24
Schonfeld Strategic Advisors
New York
$6.36K -$2.28K -425 -27%
UBS Group
25
UBS Group
Switzerland
$5.66K +$1.69K +314 +44%
1
2

NXTC Hedge Fund Activity: Q2 2025 in Review

30 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2025, worth a combined $5.65M — down 23% from $7.38M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NXTC and 2 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Cable Car Capital, adding an estimated $39.4K. The largest seller was Pfizer, cutting an estimated $776K.

  • 30 institutional investors held NextCure (NXTC) as of Q2 2025, down from 38 in Q1 2025.
  • Funds reported $5.65M of NextCure stock for Q2 2025, down 23% quarter-over-quarter.
  • 2 funds opened new NextCure positions in Q2 2025 and 10 closed out, a net change of -8 holders.
  • The largest NextCure buyer in Q2 2025 was Cable Car Capital, an estimated $39.4K added.
  • The largest NextCure seller in Q2 2025 was Pfizer, an estimated $776K sold.

Based on aggregated 13F filings for Q2 2025.